As of August 2026, HIMS's trailing twelve months (TTM) EPS stands at -$0.61, according to the latest financial reports. Hims & Hers Health's EPS for 2025 came in at $0.57, marking a decrease from $0.58 in 2024. HIMS reported an EPS of -$0.37 for the quarterly report ending on Jun 30, 2026.
For 2025, Hims & Hers Health's EPS was $0.57, a decrease of 1.7% from $0.58 in 2024. The quarterly EPS for the period ending Jun 30, 2026, was -$0.37, marking a 294.7% decrease from the same quarter last year. HIMS's TTM EPS stands at -$0.61 as of June 2026. Hims & Hers Health's EPS for 2024 stood at $0.58, a 627.3% increase from 2023.
Hims & Hers Health has recorded a decrease in EPS of 294.7% over the last 12 months (YoY, quarterly).
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| NBIX Neurocrine Biosciences Inc | 22.12 | 41.5% | 44% | 1.9% |
| NVAX Novavax Inc | N/A | 321.1% | N/A | N/A |
| NVCR NovoCure Ltd | N/A | 21.8% | N/A | N/A |
| HIMS Hims & Hers Health Inc | N/A | -1.7% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.